CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 40 enrolled
Drug / intervention
Palbociclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04439201
NCT04439201Phase 2Active
CompareCT.gov

MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CCND1, 2, 3 Amplification

National Cancer Institute (NCI)·interventional·Posted Jun 19, 2020·Updated Apr 13, 2026

In Brief

A Phase 2 clinical trial evaluating Palbociclib for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 40 participants across 1 site.

Detailed Summary

This phase II MATCH treatment trial identifies the effects of palbociclib in patients whose cancer has genetic changes called CCND1, 2, or 3 amplification. Palbociclib blocks proteins called CDK4 and CDK6, which may stop cancer cell growth when CCND1, 2, or 3 amplifications are present. Researchers hope to learn if palbociclib will shrink this type of cancer or stop its growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedJun 19, 2020
Enrollment StartMay 31, 2016
Primary CompletionMar 9, 2021
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.0 years ago

Interventions

Palbociclibdrug

Given PO